Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q3 EPS of ($1.38), $0.13 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $143 thousand versus the consensus estimate of $491 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.